These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 38509393)
1. Affinity maturation of CRISPR-engineered B cell receptors in vivo. Nat Biomed Eng; 2024 Apr; 8(4):341-342. PubMed ID: 38509393 [No Abstract] [Full Text] [Related]
2. Gene editing and gene regulation with CRISPR. Harrison P; Hart S Exp Physiol; 2018 Apr; 103(4):437-438. PubMed ID: 29603460 [No Abstract] [Full Text] [Related]
3. The Biology and Application Areas of CRISPR Technologies. Adli M J Mol Biol; 2019 Jan; 431(1):1-2. PubMed ID: 30447221 [No Abstract] [Full Text] [Related]
4. Meeting Report: German Genetics Society-Genome Editing with CRISPR. Maier LK; Marchfelder A; Randau L Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989 [No Abstract] [Full Text] [Related]
7. Foresight is 2020: Ten Bold Predictions for the New CRISPR Year. Barrangou R CRISPR J; 2019 Dec; 2(6):341-342. PubMed ID: 31860348 [No Abstract] [Full Text] [Related]
14. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches. Ahmed MZ; Badani P; Reddy R; Mishra G J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111 [TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9. Yan F; Wang W; Zhang J Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291 [No Abstract] [Full Text] [Related]
16. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591 [TBL] [Abstract][Full Text] [Related]
17. Development and application of CRISPR/Cas9 technologies in genomic editing. Zhang C; Quan R; Wang J Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822 [TBL] [Abstract][Full Text] [Related]